EURONEXT-PAR$DBVT
DBV Technologies · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
DBV Technologies reported financial results for Q1 2022 and provided business updates on Viaskin Peanut's regulatory status.
DBV Technologies reported a net loss of $16.7 million for the first quarter of 2022, with cash and cash equivalents totaling $74.1 million. The FDA granted a Type C meeting to align on the new Viaskin Peanut Phase 3 study protocol. The company expects its current cash and cash equivalents to support operations into Q1 2023.
- FDA granted DBV Technologies a Type C meeting to align on the new Viaskin Peanut Phase 3 study protocol.
- The study protocol was submitted to the FDA as part of the Type C briefing materials.
- Cash and cash equivalents were $74.1 million as of March 31, 2022.
- DBV expects top-line results of the EPITOPE trial by the end of Q2 2022.
Headline financials
Revenue & EPS history
DBV Technologies · Revenue · Quarterly
€2.55M
Forward guidance
DBV expects that its current cash balance will sufficiently support Company operations while alignment with the FDA on the VITESSE protocol is achieved and anticipates its current cash and cash equivalents will support its operations into the first quarter of 2023.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2022
+0.3%
Avg return
Earnings day
+0.2%
Avg return
5 days after
+11.4%
Avg return
30 days after
47%
20 / 43 earnings
Positive
+21.6%
Q4 2018
Best reaction
-29.8%
Q3 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +2.7% | -4.3% | -83.9% | |
| Q3 2025 | -1.2% | -5.4% | -1.4% | |
| Q1 2025 | -4.4% | +4.2% | -7.3% | |
| Q4 2024 | +7.5% | +0.9% | -1.4% | |
| Q3 2024 | -2.5% | -11.3% | +380.9% | |
| Q1 2024 | +3.7% | -14.0% | -15.4% | |
| Q4 2023 | +1.2% | +1.1% | -9.6% | |
| Q3 2023 | -2.9% | -1.9% | -29.5% | |
| Q2 2023 | +1.9% | -2.5% | -3.2% | |
| Q1 2023 | +5.8% | +4.5% | +27.6% | |
| Q4 2022 | -0.7% | +4.1% | +16.6% | |
| Q3 2022 | +2.7% | +2.0% | -9.5% | |
| Q2 2022 | -5.5% | +3.5% | -21.2% | |
| Q1 2022 | -1.6% | +6.2% | +19.4% | |
| Q4 2021 | +3.1% | +0.8% | +22.3% | |
| Q3 2021 | -29.8% | -40.9% | -41.3% | |
| Q2 2021 | -4.4% | -8.1% | +7.7% | |
| Q1 2021 | -1.1% | +0.6% | +21.4% | |
| Q4 2020 | -0.4% | +2.9% | +86.2% | |
| Q3 2020 | +0.0% | -3.5% | -16.4% | |
| Q2 2020 | -3.0% | -3.5% | -16.8% | |
| Q1 2020 | -7.7% | -7.7% | +53.6% | |
| Q4 2019 | -1.2% | +3.6% | -11.7% | |
| Q3 2019 | -0.4% | +4.0% | -13.7% | |
| Q2 2019 | +5.5% | +26.5% | +17.2% | |
| Q1 2019 | -1.7% | +14.3% | +26.5% | |
| Q4 2018 | +21.6% | +34.8% | +16.3% | |
| Q3 2018 | -2.7% | -14.8% | -18.9% | |
| Q2 2018 | -1.9% | -0.1% | -8.2% | |
| Q1 2018 | -1.3% | +3.7% | -4.9% | |
| Q4 2017 | +3.5% | +7.8% | -4.7% | |
| Q3 2017 | +5.5% | -3.4% | +17.2% | |
| Q2 2017 | +1.4% | +1.3% | +25.0% | |
| Q1 2017 | -0.3% | -1.7% | +1.3% | |
| Q4 2016 | -1.1% | -0.4% | -1.0% | |
| Q3 2016 | +1.1% | +1.9% | -2.7% | |
| Q2 2016 | +3.5% | +0.6% | +6.8% | |
| Q1 2016 | +6.7% | — | — | |
| Q4 2015 | -2.3% | — | — | |
| Q3 2015 | +3.7% | — | — | |
| Q2 2015 | +4.3% | — | — | |
| Q1 2015 | +0.4% | — | — | |
| Q4 2014 | +5.2% | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro